A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...

This week, Bobbi Conner talks with MUSC's Dr. Vanessa Hinson about research underway to explore the use of stem cell therapy ...

January 27, 2009 — Geron Corp announced it has received US Food and Drug Administration (FDA) approval for a phase 1 trial of GRNOPC1, a cell therapy derived from human embryonic stem cells (hESC), in ...

Dr Jitesh Neupane discusses his hematoids model and opportunities to study childhood blood disorders and future stem cell therapies.

Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...

The global stem cell therapy market is projected to experience robust growth, with an expected annual growth rate of 20% by 2029. Key drivers behind this expansion include a favorable investment ...

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical ...

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT Technology World's First Therapy Platform Simultaneously Solving ...

Japan’s health ministry has granted conditional, time-limited authorization for two stem-cell therapies derived from induced pluripotent stem (iPS) cells, endorsing them for use based on early safety ...